Protagonist Therapeutics (PTGX) Projected to Announce Earnings on Thursday

Key Points

• Protagonist Therapeutics is expected to report Q3 2026 results after market close on Thursday, November 5. Analysts forecast earnings of $2.50 per share and revenue of $238.49 million.
• The company exceeded expectations in its latest quarter, reporting $2.29 EPS versus the $2.27 consensus and $213.47 million in revenue. Revenue increased 3,746.8% year over year.
• PTGX shares recently opened at $142.14, while analysts maintain a consensus “Buy” rating and a $163.27 price target. However, insiders have sold approximately $41.4 million of stock over the past 90 days.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) is anticipated to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Protagonist Therapeutics to post earnings of $2.50 per share and revenue of $238.49 million for the quarter. Individuals may review the information on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 2, 2026 at 4:00 PM ET.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $2.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.27 by $0.02. Protagonist Therapeutics had a return on equity of 12.03% and a net margin of 29.40%. The firm had revenue of $213.47 million for the quarter, compared to analyst estimates of $212.03 million. The business's revenue was up 3746.8% on a year-over-year basis. On average, analysts expect Protagonist Therapeutics to post $4.59 EPS for the current fiscal year and $0.11 EPS for the next fiscal year.

Protagonist Therapeutics Price Performance

Shares of Protagonist Therapeutics stock opened at $142.14 on Thursday. The business has a 50-day moving average of $143.26 and a 200 day moving average of $115.82. Protagonist Therapeutics has a 12 month low of $75.44 and a 12 month high of $160.81. The stock has a market capitalization of $9.20 billion, a price-to-earnings ratio of 138.00 and a beta of 1.53.

Insider Buying and Selling

In related news, CEO Dinsesh Patel sold 7,278 shares of the firm's stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $144.10, for a total value of $1,048,759.80. Following the sale, the chief executive officer owned 522,968 shares of the company's stock, valued at $75,359,688.80. This trade represents a 1.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Asif Ali sold 58,629 shares of Protagonist Therapeutics stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $141.78, for a total transaction of $8,312,419.62. Following the completion of the transaction, the chief financial officer owned 59,003 shares of the company's stock, valued at $8,365,445.34. This represents a 49.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 283,629 shares of company stock worth $41,443,786 over the last 90 days. Insiders own 5.19% of the company's stock.

Analyst Upgrades and Downgrades

PTGX has been the topic of several research reports. Wedbush increased their price target on shares of Protagonist Therapeutics from $118.00 to $173.00 and gave the stock an "outperform" rating in a research report on Monday, August 10th. TD Cowen lifted their price objective on shares of Protagonist Therapeutics from $155.00 to $160.00 and gave the company a "buy" rating in a report on Wednesday, October 21st. Weiss Ratings cut shares of Protagonist Therapeutics from a "buy (b-)" rating to a "hold (c+)" rating in a report on Friday, October 23rd. Leerink Partners initiated coverage on shares of Protagonist Therapeutics in a research note on Monday, October 12th. They set an "outperform" rating and a $190.00 target price on the stock. Finally, Wall Street Zen lowered shares of Protagonist Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Saturday, October 10th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $163.27.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc is a biopharmaceutical company focused on discovering and developing peptide-based medicines for immune-mediated and hematologic diseases. The company uses its proprietary peptide technology platform to design therapies intended to act on specific biological pathways and receptors.

Its leading program is icotrokinra, also known as JNJ-2113, an oral, targeted inhibitor of the interleukin-23 receptor being developed in collaboration with Janssen Pharmaceuticals for inflammatory and immune-mediated conditions, including psoriasis and inflammatory bowel diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.